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A GPR40 Agonist GW9508 Suppresses CCL5,
CCL17, and CXCL10 Induction in Keratinocytes
and Attenuates Cutaneous Immune Inflammation
Tomoko Fujita1,2, Toshiyuki Matsuoka1,2, Tetsuya Honda3, Kenji Kabashima1,3, Takako Hirata1,2
and Shuh Narumiya1,2
G-protein coupled receptors (GPCR) exert diverse physiological functions, many of which are exploited
therapeutically. The roles of GPCR in keratinocytes in immune response in the skin, however, remain poorly
defined. In this study, we focused on Gi-coupled GPCR in keratinocytes and defined their actions in
immunoactivation of cultured keratinocytes in vitro and immune reaction in the skin in vivo. We first activated
HaCaT cells by tumor necrosis factor (TNF)-a and IFN-g and examined effects of various ligands for GPCR on
production of CCL17 and CCL5. Agonists for Gi-coupled receptors, particularly GW9508 for GPR40, inhibited
CCL17 and CCL5 expression in a pertussis toxin-sensitive manner. The inhibitory effect by GW9508 was
abrogated by depletion of GPR40 with RNA interference. GW9508 further suppressed expression of IL-11, IL-24,
and IL-33 induced in HaCaT cells by TNF-a and IFN-g. GW9508 also inhibited CCL5 and CXCL10 production
by normal human epidermal keratinocytes. Administration of GW9508 topically to the skin in the challenging
phase suppressed ear swelling in a repeated hapten application model and contact hypersensitivity with
downregulation of CCL5 and CXCL10, respectively. Thus, in the skin, stimulation of Gi-coupled receptors
attenuates induction of critical cytokines and chemokines by proinflammatory cytokines in keratinocytes and
suppresses allergic inflammation in the skin.
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INTRODUCTION
G-proteins consisting of a, b, and g subunits are signal
transducers and mediate actions of G-protein coupled
receptors (GPCR) with seven transmembrane domains in
the plasma membrane (Neves et al., 2002). Each GPCR is
coupled to either a different class of G-proteins, Gs, Gi, Gq,
or G12/13, or a combination thereof. Gsa activates adenylate
cyclase, and raises the intracellular concentration of cAMP.
On the other hand, Gia inhibits adenylate cyclase and
decreases intracellular cAMP. Among more than 1,000 GPCR
encoded by mammalian genomes, up to 400–500 GPCR
recognize neurotransmitters, hormones, and paracrine
factors, whereas others are involved in sensory functions
such as taste or odor perception. Notably, about half of all
drugs currently used clinically target GPCR in various
systems from the central nervous system to the cardiovascular
system. However, the role of GPCR in the immune system
remains obscure and their therapeutic application in this area
has been limited to those for chemokines and other
chemotactic substances such as sphingosine-1-phosphate
(Rosen et al., 2007). GPCR have been generally viewed as
mediating immunosuppression through elevation of intra-
cellular cAMP in cells such as macrophages and T cells
(Nance and Sanders, 2007). However, contrary to this
oversimplified view, recent studies have indicated that GPCR
have diverse roles in immunity depending on the context of
immune response. For example, we have recently shown
that stimulation of the cAMP pathway by prostaglandin
E receptors EP2 and EP4 exerts significant facilitation of Th17
expansion by regulating IL-23 expression by dendritic cells
and enhancing the IL-23-induced Th17 amplification
(Yao et al., 2009). These findings have questioned the simple
paradigm of the immunosuppression by cAMP and suggest
that the action of a GPCR in the immune system has to be
defined in the contexts of target cells and tissues, timing of
stimulation, types of other combined stimuli, and output of
the response at various levels.
The incidence and severity of allergic skin diseases such as
contact hypersensitivity (CHS) and atopic dermatitis (AD)
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have increased extensively over the last 20 years in
developed countries, and drugs targeted to these diseases
are urgently demanded. In these allergic diseases, keratino-
cytes have a crucial role in disease progression (Girolomoni
et al., 2004; Pastore et al., 2006). We previously reported that
administration of an agonist of prostaglandin E receptor EP3,
a Gi-coupled receptor, attenuates allergic asthma (Kunikata
et al., 2005), CHS (Honda et al., 2009), and allergic
conjunctivitis (Ueta et al., 2009). Stimulation of cannabinoid
CB1 and CB2 receptors, both coupled to Gi, has also been
shown to induce attenuation of DNFB-induced CHS (Karsak
et al., 2007). Although EP3 is expressed on epithelial cells in
the airway and conjunctiva and keratinocytes in the skin
and EP3 in these cells is suggested to mediate the above
therapeutic action, a direct proof of the involvement of
Gi-coupled receptors in keratinocytes in such action is
lacking. In this study, we first sought to define the actions
of Gi-coupled receptors in cultured keratinocytes and then to
analyze the effects of such pathway in elicitation of immune
inflammation in the skin. Here, we used HaCaT, a human
epidermal keratinocyte cell line, normal human epidermal
keratinocytes (NHEKs), and mouse models of AD and CHS,
and addressed these issues.
RESULTS
GPR40 agonist GW9508 suppresses CCL17 production through
pertussis toxin-sensitive Gi protein
We first used HaCaT human epidermal keratinocyte cell line.
Previous reports showed that HaCaT cells produce CCL17 in
response to stimulation with tumor necrosis factor (TNF)-a
or IFN-g alone, or TNF-a and IFN-g in combination
(TNF-aþ IFN-g; Saeki and Tamaki, 2006). We exploited this
finding and reproduced synergistic production of CCL17 by
TNF-aþ IFN-g in HaCaT cells, both at mRNA and protein
levels (Figure 1a). We also found that TNF-a and IFN-g
synergistically enhance CCL5 production by HaCaT cells
(Figure 1b). CCL17 and CCL5 are produced by keratinocytes
in inflammatory states and have crucial roles in Th2-type
immune responses such as AD (Pastore et al., 2006; Saeki
and Tamaki, 2006). To screen GPCR ligands that inhibit the
TNF-aþ IFN-g-induced chemokine expression, we examined
the activity of compounds in the Tocriscreen Mini library in
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Figure 1. Inhibition by GW9508 of tumor necrosis factor (TNF)-aþ IFN-c-induced production of CCL17 and CCL5 in HaCaT cells. CCL17 (a) and CCL5
(b) production by TNF-a and/or IFN-g. Inhibitory effect of GW9508 on TNF-aþ IFN-g-induced CCL17 (c) and CCL5 (d) production. Effect of pertussis toxin
(PTX) (e and f) and forskolin (g) on TNF-aþ IFN-g-induced CCL17 and CCL5 production. TI, TNF-aþ IFN-g; veh, vehicle. Quantitative real-time
RT-PCR data are shown as arbitrary units (a.u.) where the value for unstimulated sample is set at 1. Results show a representative of three independent
experiments. Data show mean±SEM (n¼ 3). *Po0.05, **Po0.01, ***Po0.001 versus TIþ veh in (c–f).
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this system with CCL17 as a parameter. This screening
revealed that several agonists for putative Gi-coupled
receptors, such as ST91 for a2 adrenergic receptor, GP1a
and GP2a for CB2, 30-fluorobenzyl-spiperone for dopamine
D2, and GW9508 for GPR40 potently suppressed the
TNF-aþ IFN-g-induced CCL17 production (Supplementary
Table S1 online). The presence of these receptors in HaCaT
cells was confirmed by GPCR array analysis and indicated as
DCt (Supplementary Table S1 online). We chose GW9508 for
further analysis, because it most potently suppressed CCL17
expression. To verify the finding in the screening, we
examined the dose dependency of the inhibitory effect of
this compound on CCL17 and CCL5 by quantitative real-time
RT-PCR (QRT-PCR) and ELISA. We found the concentration-
dependent suppression of both CCL17 and CCL5 mRNA and
protein production by GW9508 in HaCaT cells (Figure 1c
and d) without any significant effect on their viability
(Supplementary Figure S1 online). This inhibitory action of
GW9508 was reversed by low doses of pertussis toxin (PTX;
Figure 1e,), verifying that GPR40 stimulation exerts such
effects through Gi. Conversely, forskolin, an adenylate
cyclase activator, enhanced TNF-aþ IFN-g-induced
production of CCL17 and CCL5 (Figure 1g). On the other
hand, inhibitors of AKT, PI3 kinase, p38 MAPK, MEK, and Src
did not reverse the effect of GW9508 (data not shown). These
results collectively suggest that PTX-sensitive Gi signal-
ing suppresses CCL17 and CCL5 production induced by
TNF-aþ IFN-g through decrease in cAMP.
Although GW9508 is an agonist of GPR40, it also acts
on GPR120 at higher concentrations (pEC50¼7.32±0.03
and pEC50¼5.46±0.09, respectively; Briscoe et al, 2006).
Reverse transcription PCR analysis detected expression
of both GPR40 and GPR120 mRNA in HaCaT cells
(Figure 2a). To verify that the immunosuppressive effect is
mediated by GPR40, we knocked down GPR40 with
RNA interference. Small interfering RNA for GPR40 signifi-
cantly decreased the amount of GPR40 mRNA compared
with control small interfering RNA after 72 hours (Figure 2b).
Depletion of GPR40 by this procedure reversed the
suppressive effect of 1mM GW9508 on CCL17 and CCL5
production (Figure 2c), corroborating that GW9508 exerts
its inhibitory effect through GPR40 and not GPR120 in
HaCaT cells.
GW9508 inhibits CCL5 and CXCL10 production by NHEK
To further corroborate the findings in HaCaT cells, we next
used primary culture of NHEKs. NHEK cells expressed
GPR40 but not GPR120 (Figure 3a). Consistent with a
previous report (Tsuda et al., 2003), we did not find
significant production of CCL17 by NHEK on stimulation
with TNF-a, IFN-g, or TNF-aþ IFN-g (data not shown).
On the other hand, we noted induction of CCL5 by IFN-g
alone, and found that this induction was concentration-
dependently inhibited by GW9508 (Figure 3b). Under the
same conditions, we also noted production of CXCL10,
which was also inhibited by GW9508 (Figure 3c). Again,
GW9508 was without effect on viability of NHEK (Supple-
mentary Figure S1 online). Therefore, GW9508 suppresses
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Figure 2. GPR40 expression in HaCaT cells and GPR40 knockdown
experiments. (a) GPR40 and GPR120 mRNA. Data of two different batches
of HaCaT cells are shown. (), Control without template. (b) Reduction of
GPR40 mRNA by small interfering RNA (siRNA) treatment. (c) Reversal of
GW9508-mediated inhibition of CCL17 (left) and CCL5 (right) mRNA
expression by GPR40 depletion. Control, control siRNA. Bars¼ 50mm.
Results show a representative of three independent experiments. Data show
mean±SEM (n¼ 3). *Po0.05, **Po0.01, ***Po0.001 versus control RNA
interference (b) or TIþ veh (c).
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Figure 3. Effects of GW9508 on CCL5 and CXCL10 production in NHEK.
Reverse transcription PCR analysis of GPR40 and GPR120 mRNA (a) and
inhibition by GW9508 of CCL5 (b) and CXCL10 (c) production in normal human
epidermal keratinocyte (NHEK). In (a), data of two different batches of NHEK are
shown. (), Control without template. QRT-PCR data are shown as arbitrary units
(a.u.) where the value for unstimulated sample is set at 1 (b and c, left). Veh,
vehicle. Results show a representative of three independent experiments. Data
show mean±SEM (n¼ 3). *Po0.05 versus IFN-gþ veh.
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IFN-g-induced CCL5 and CXCL10 production through
GPR40.
Changes in gene expression pattern after GW9508 treatment
Previous studies reported that besides CCL17, many chemo-
kines and cytokines are also markedly elevated in HaCaT
cells after combined stimulation with TNF-aþ IFN-g
(Xiao et al., 2003; Lee et al., 2009; Lo et al., 2010). Therefore,
we speculated that many other proinflammatory proteins are
upregulated by TNF-aþ IFN-g and that their expression
might be differentially regulated by GPR40 stimulation.
We conducted comparative microarray analyses for gene
expression and noted that 16 cytokines and 13 chemokines
were upregulated more than 2-fold 24 hours after the
TNF-aþ IFN-g stimulation (Supplementary Table S2 online).
GW9508 treatment resulted in no further upregulation of any
genes but induced reduction of expression of five genes,
CCL17, CCL5, IL-11, IL-24, and IL-33 (Supplementary
Table S3 online). IL-33 is a Th2-related cytokine, which
activates basophils and acts on dendritic cells to promote
Th2 immunity (Kakkar and Lee, 2008) and its expression
is elevated in lesional skin of AD patients (Pushparaj et al.,
2009).
Suppression by GW9508 of ear inflammation by repeated
DNFB treatment
The above results demonstrate that stimulation of GPR40
suppresses the cytokine-induced expression of CCL17
and CCL5 in HaCaT cells and that of CCL5 and CXCL10 in
NHEK. To assess the in vivo effects of GPR40 stimulation, we
examined whether treatment with GW9508 could exert
effects expected from the in vitro experiments in cutaneous
immune inflammation models. We first examined GPR40
expression in keratinocytes of the mouse ear. Reverse
transcription PCR analysis of the whole ear showed a similar
extent of GPR40 mRNA expression in this tissue of BALB/c
and C57BL/6 mice (Figure 4a). In situ hybridization for
GPR40 mRNA further showed that GPR40 was expressed in
the epidermis of BALB/c mice (Figure 4b) and in the
epidermis and the dermis of C57BL/6 mice (Figure 4c).
Reverse transcription PCR did not detect GPR120 mRNA
expression in mouse epidermis (Figure 4a).
To examine effects of GW9508 on a Th2-type inflamma-
tion, we adopted repeated DNFB treatment in BALB/c mice.
Repeated elicitation with hapten results in a shift from
Th1-mediated to Th2-mediated inflammation (Kabashima
et al., 2003; Inagaki et al., 2006), which mimics AD. From
the fifth to the ninth elicitation, we applied 20 ml of 200mM
GW9508 or vehicle topically to the ear 1 h before each
DNFB application. Treatment with GW9508 resulted in
significant reduction of ear swelling compared with the
control mice (Figure 5a). Histological examination revealed
diminished epidermal thickening and attenuated cell infiltra-
tion in the dermis of the GW9508-treated group compared
with the vehicle-treated group (Figure 5b). We next examined
the expression of CCL17 or CCL5 in the epidermis. QRT-PCR
analysis revealed that, although expression of CCL17 showed
no elevation in either group compared with the
non-immunized, non-challenged group, CCL5 expression
was significantly elevated in the immunized, challenged
and vehicle-treated group (the vehicle-treated group) and the
GW9508 treatment significantly attenuated the expression of
this chemokine compared with that found in the vehicle-
treated group (Figure 5c). Immunostaining for CCL5 revealed
that the CCL5 signal was enriched in the cytoplasm of
keratinocytes of the skin of the vehicle-treated animals, and
that the GW9508 treatment markedly attenuated the signal
(Figure 5d). Consistent with this suppression, the number
of eosinophils infiltrating in the skin was significantly
suppressed in the GW9508-treated group compared with
the control, vehicle-treated group (Figure 5b and e).
Attenuation of mast cell infiltration was also noted in the
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Figure 4. GPR40 and GPR120 expression in mouse epidermis. (a) Reverse
transcription PCR (RT-PCR) of GPR40 mRNA expression in the ear
(upper row) and GPR120 mRNA expression in the epidermis (lower row) of
BALB/c and C57BL/6 mice. Mouse lung cDNA was used as a positive control
for PCR of GPR120 (Hirasawa et al., 2005). (), Control without template.
(b,c) In situ hybridization for GPR40 mRNA in unstimulated ears of BALB/c
mice (b) and C57BL/6 mice (c). Left, hybridization with antisense probe;
right, hybridization with sense probe. Positive signals are indicated
with arrows. Bars¼ 100mm. A representative of three independent
experiments is shown.
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GW9508-treated group (Figure 5f). These data collectively
suggest that GW9508 reduces CCL5 production in keratino-
cytes and infiltration of eosinophils and mast cells,
and attenuates ear swelling in repeated DNFB treatment, a
model of AD.
Suppression by GW9508 of elicitation of CHS
We next examined whether GPR40 stimulation has a
suppressive effect also in Th1-type skin inflammation,
because GPR40 stimulation inhibited CXCL10 production
in NHEK. CXCL10 recruits Th1 cells and is known to have
important roles in Th1-type immune responses (Nakae et al.,
2003). To this end, we subjected wild-type C57BL/6 mice
to DNFB-induced CHS and treated mice with different
concentrations of GW9508 topically to the ear 30minutes
before the challenge. Application of GW9508 suppressed ear
swelling in a concentration-dependent manner (Figure 6a).
Histological examination revealed marked attenuation of
epidermal thickening and infiltration of cells in the dermis in
the GW9508-treated group (Figure 6b). QRT-PCR analysis of
the whole ear showed marked elevation of CXCL10 mRNA
expression in mice subjected to CHS, and this increase was
significantly suppressed by GW9508 treatment (Figure 6c).
Changes in expression of CCL5 and CCL17 could not be
detected, probably because the mouse CHS is Th1-dependent
and not Th2-dependent immune inflammation. Immuno-
staining for CXCL10 exhibited strong accumulation of this
chemokine in the epidermis of the vehicle-treated group,
which was markedly attenuated by GW9508 treatment
(Figure 6d). Taken together, these results suggest that
GW9508 attenuates CHS at least in part by suppressing
CXCL10 expression by keratinocytes.
DISCUSSION
Keratinocytes are a major cellular component of the skin and
have a key role in establishing local inflammatory milieu in
various cutaneous diseases (Pastore et al., 2006). In this
study, we screened Gi-coupled GPCR expressed in HaCaT
cells by chemical library screening and GPCR array, and
found GPR40 as one of them. Stimulation of GPR40
suppresses expression of CCL17 and CCL5 in vitro in HaCaT
cells stimulated with TNF-aþ IFN-g and CCL5 and CXCL10
expression in NHEK stimulated with IFN-g. Furthermore,
stimulation of GPR40 suppresses immune inflammation
in vivo in the skin in the mouse.
CCL17 is a ligand for CCR4, which is mainly expressed
on Th2 cells. CCL17 is produced by diverse cell types,
including bronchial epithelial cells, fibroblasts, endothelial
cells, and dendritic cells in addition to HaCaT cells (Saeki
and Tamaki, 2006). Although we have not detected elevation
of CCL17 in our mouse model for AD, keratinocytes in skin
lesion of AD patients are stained positive for CCL17. Further,
the serum concentration of CCL17 is significantly higher in
AD patients than in psoriasis vulgaris subjects or normal
healthy donors, and correlates well with the severity of AD
(Kakinuma et al., 2001). These findings suggest that CCL17
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Figure 5. Inhibition by GW9508 of immune inflammation with repeated DNFB treatment, a model of atopic dermatitis. (a) Time course of ear swelling
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has a key role in the pathogenesis of AD in humans. Given
the suppression of CCL17 expression by GPR40 stimulation
in HaCaT cells, it may be worthwhile to test the effect of a
GPR40 agonist on CCL17 expression in the skin of AD
patients.
CCL5 is a chemokine secreted by platelets, fibroblasts,
airway epithelial cells (Castellani et al., 2007), and epidermal
keratinocytes (Yamada et al., 1997; Park et al., 2005). CCL5
promotes migration of T cells, dendritic cells, eosinophils,
natural killer cells, mast cells, and basophils (Levy, 2009).
Recently, single-nucleotide polymorphism was found in the
promoter region of CCL5 gene, and significant association of
the variant with enhanced promoter activity with AD was
reported (Nickel et al., 2000; Tanaka et al., 2006). In the
present work, we found the elevation of CCL5 in the
epidermis with repeated DNFB treatment in the mouse
model of AD, and that GW9508 treatment attenuated ear
swelling in this model with concomitant decrease of the
CCL5 production in the epidermis. Suppression of infiltration
of eosinophils and mast cells was also observed with
GW9508 treatment. Our results are thus consistent with the
above genomic study and suggest that GPR40 stimulation
inhibits Th2-type skin inflammation in part by inhibiting
CCL5 expression by keratinocytes.
We also examined effects of GPR40 stimulation in CHS, a
Th1-dependent inflammation. In CHS, keratinocytes produce
many chemokines to attract inflammatory cells to the site
of inflammation. Among them, CXCL10 is one of the most
important chemokines in CHS pathogenesis (Nakae et al.,
2003; Mori et al., 2008). CXCL10 is a ligand for CXCR3,
which is primarily expressed on Th1 cells. CHS response was
decreased in TNF-a deficient mice, which was reversed by
CXCL10 injection during the elicitation phase. Moreover,
CHS was suppressed by treatment with anti-CXCL10 mAb,
suggesting a critical role for CXCL10 in CHS (Nakae et al.,
2003). We found that GW9508 suppressed ear swelling
and dermal infiltration of inflammatory cells in CHS with
concomitant suppression of CXCL10 expression in keratino-
cytes. In conclusion, GPR40 stimulation inhibits chemokine
production by keratinocytes in not only Th2-dependent but
also Th1-dependent skin inflammation, and suppresses
progression of the inflammation.
GPR40, a Gi- and Gq-coupled GPCR, is a recently
deorphanized long-chain free fatty acid receptor (Itoh et al.,
2003). It is abundantly expressed on pancreatic b cells and
stimulates insulin secretion. The actions of GPR40 in the
immune system are currently unknown. Our findings suggest
that GPR40 expressed in the skin regulates cutaneous
immune responses. Keratinocytes proliferate at the basal
layer of the epidermis and differentiate as they migrate
toward the surface. The outermost layer of the epidermis, the
stratum corneum, serves as a rigid barrier, which prevents
water loss and the entry of pathogens into the dermis (Proksch
et al., 2008). Intracellular components of the barrier function
of stratum corneum consist of keratins and filaggrin, whereas
the extracellular components consist of long-chain free fatty
acids, cholesterol, and ceramide. Essential free fatty acid
deficiency (Feingold, 2007) or defective fatty acid transport
(Klar et al., 2009) causes skin barrier defects characterized by
red and scaly skin, severe bacterial infection, and impaired
wound healing. Our present findings may indicate that long-
chain free fatty acids in the skin not only form a barrier, but
also suppress abnormal immune responses by stimulating
GPR40 to protect terrestrial organisms from water loss and
noxious stimuli. In the mouse ear, GPR40 is expressed in the
epidermis. Quite recently, GPR120, a GPCR related to
GPR40, functions as a receptor for o-3 unsaturated fatty
acids and exerts anti-inflammatory actions (Oh da et al.,
2010). Although GW9508 can act also on GPR120 at higher
concentrations (Briscoe et al, 2006), our small interfering
RNA experiments as well as expression study suggest that
GW9508 acts on GPR40 and not GPR120 to exert immuno-
suppressive effect on keratinocytes both in vitro and in vivo.
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Figure 6. Inhibition of contact hypersensitivity by topical application of
GW9508. (a) Effect of GW9508. No sens., group without sensitization
and treated with 0.3% DNFB; veh, vehicle-treated group; GW9508,
GW9508-treated group. (b) Hematoxylin–eosin staining. (c) QRT-PCR
analysis of CXCL10 mRNA. Data are shown as arbitrary units (a.u.) where the
value for the group without sensitization is set at 1. (d) Immunostaining for
CXCL10. Bars¼ 100mm. Results are representative of three independent
experiments. Data show mean±SEM of five mice. *Po0.05 compared
with vehicle.
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Our present findings that stimulation of a Gi-coupled
receptor, GPR40, suppresses immune inflammation in the
skin are consistent with previous reports by our laboratories
and others on other Gi-coupled GPCR such as PGE receptor
EP3 subtype and CB1 and CB2 cannabinoid receptors.
Stimulation of EP3 inhibits experimental allergic conjuncti-
vitis (Ueta et al., 2009), allergic airway inflammation
(Kunikata et al., 2005), and CHS (Honda et al., 2009) in
mice, and stimulation of CB1 and CB2 suppresses CHS
(Karsak et al., 2007). These results suggest that Gi-coupled
GPCR including GPR40 can be a good candidate for drug
development against allergic diseases targeted to the epithe-
lium.
MATERIALS AND METHODS
Mice
Female BALB/c mice and C57BL/6NCrSlc mice, 7–11 weeks of age,
were obtained from Japan SLC (Hamamatsu, Japan). They were
housed at the Institute of Laboratory Animals of Kyoto University on
a 12-hours light/dark cycle under specific pathogen-free conditions.
All experimental procedures were approved by the Committee on
Animal Research of Kyoto University Faculty of Medicine.
Reagents and cytokines
Tocriscreen Mini library containing GW9508 was from Tocris
Cookson (Avonmouth, UK). PTX was from List Biological Labora-
tories (Campbell, CA). Forskolin was from Sigma-Aldrich (St Louis,
MO). Human TNF-a and IFN-g were from Peprotech (Rocky Hill,
NJ). DNFB was from Nacalai Tesque (Kyoto, Japan).
Cell culture
HaCaT cells (Boukamp et al., 1988; Cell Lines Service, Eppelheim,
Germany) were cultured in high glucose DMEM (Gibco, Carlsbad,
CA) supplemented with 50Uml1 penicillin, 50 mgml1 streptomy-
cin (Nacalai Tesque) and 10% fetal bovine serum (Gibco). They
were seeded at 2 104 cells per well in a 96-well plate in 200 ml of
the above medium containing serum. After 24 hours, the medium
was replaced with the serum-free medium and the cells were
cultured for another 24 hours. The medium was then changed with
fresh serum-free medium, and drugs were added to the cells. After
5minutes, 10 ngml1 TNF-a and/or 10 ngml1 IFN-g were added
and the cells were cultured for indicated times. After incubation,
the medium was saved for ELISA and the cells were lysed for
RNA preparation for QRT-PCR. NHEK (KURABO, Osaka, Japan)
were cultured in HuMedia–KG2 (KURABO) supplemented with
insulin, bovine pituitary extract, epidermal growth factor, hydro-
cortisone, kanamycin, and amphotericin B. They were seeded at
2 104 cells per well in 96-well plates. After 24 hours, medium was
replaced with HuMedia-KG2 without supplements and cultured
for 24 hours. The medium was then changed and treated with
GW9508 and stimulated with cytokines as described for HaCaT
cells.
Repeated DNFB treatment and CHS protocol
Repeated DNFB treatment was performed essentially as described
(Inagaki et al., 2006). From the fifth to the ninth elicitation, 10 ml of
200mM GW9508 in 99% ethanol was topically applied to each ear
on days of elicitation 1 hour before DNFB treatment. Ears were
collected 6 hours after the last elicitation. Mice treated with vehicle
without DNFB were used as control. CHS was performed essentially
as described (Honda et al., 2009). GW9508 was administered
topically to the ear 30minutes before elicitation. Ear thickness was
measured with a micrometer before and 24 hours after challenge to
assess inflammation. Ears were then collected for histology and
QRT-PCR analysis.
For other methods including GPCR array, QRT-PCR, RT-PCR,
ELISA, microarray experiments, MTT assay, RNA interference,
histological studies, and in situ hybridization, see Supplementary
Materials and Methods online. Primers used for QRT-PCR and RT-
PCR are indicated in Supplementary Table S4 online.
Statistical analysis
Data were expressed as means±SEM, and statistical analyses were
performed by means of Student’s t-test. A P value o0.05 was
considered to be statistically significant.
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